PRV 3279

Drug Profile

PRV 3279

Alternative Names: Anti-CD32B-anti-CD79B-bispecific-monoclonal-antibody; CD32BxCD79B; MGD 010; PRV-3279

Latest Information Update: 16 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MacroGenics
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action CD79 antigen modulators; Fc gamma receptor IIB modulators; IgG receptor modulators; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Autoimmune disorders

Most Recent Events

  • 09 May 2018 PRV 3279 is still in phase I trial for Autoimmune disorders in USA
  • 09 May 2018 Provention Bio in-licenses MGD 010 from MacroGenics
  • 09 May 2018 Provention Bio plans a phase Ib/IIa trial for Systemic lupus erythematosus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top